Biotech and pharma organisations are calling for EU countries to harmonise regulations, or otherwise face falling behind in cutting-edge gene and cell therapy trials.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
